Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
10 août 2023 16h04 HE
|
Celcuity Inc.
Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countriesPresented updated results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer...
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
03 août 2023 07h30 HE
|
Celcuity Inc.
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it...
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
31 juil. 2023 08h00 HE
|
Celcuity Inc.
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that...